The Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs

Journal of Biological Chemistry

Volumn 288, Issue 19, 2013, Pages 13269-13277

  Atsumi, Yuko ^a,b   Inase, Aki ^a   Osawa, Tomoyuki ^a,c   Sugihara, Eiji ^d   Sakasai, Ryo ^e   Fujimori, Hiroaki ^a   Teraoka, Hirobumi ^e   Saya, Hideyuki ^d   Kanno, Masamoto ^f   Tashiro, Fumio ^c   Nakagama, Hitoshi ^a   Masutani, Mitsuko ^a   Yoshioka, Ken Ichi ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER DRUG; CANCER CELLS; CELLULAR TRANSFORMATION; DNA DAMAGES; DNA DAMAGING AGENTS; DOWN-REGULATION; SOMATIC CELLS;

DNA;

CELL DEATH;

ANTINEOPLASTIC AGENT; ARF PROTEIN; CAMPTOTHECIN; CELL DNA; CISPLATIN; DOXORUBICIN; HISTONE GAMMAH2AX; HISTONE H2AX; PROTEIN P53; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL SURVIVAL; CELL TRANSFORMATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TARGET CELL DESTRUCTION;

ΓH2AX; ARF; ARF/P53 MODULE; CAMPTOTHECIN; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL BIOLOGY; DNA DAMAGE RESPONSE; H2AX; P53;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL AGING; CELL SHAPE; CELLS, CULTURED; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; DNA REPLICATION; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; HYDROXYUREA; MICE; MICE, KNOCKOUT; MUTATION; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84877707148     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.402560     Document Type: Article

References (42)

1. Druker, B. J. (2003) David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J. Clin. Oncol. 21, 239s-245s
2. Vanneman, M., and Dranoff, G. (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251
3. Bernier, J. (2005) Alteration of radiotherapy fractionation and concurrent chemotherapy. A new frontier in head and neck oncology? Nat. Clin. Pract. Oncol. 2, 305-314
4. Folprecht, G., and Köhne, C. H. (2005) Drug Insight. Metastatic colorectal cancer. Oral fluoropyrimidines and new perspectives in the adjuvant setting. Nat. Clin. Pract. Oncol. 2, 578-587
5. Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584
6. Midgley, R., and Kerr, D. J. (2005) Adjuvant chemotherapy for stage II colorectal cancer. The time is right! Nat. Clin. Pract. Oncol. 2, 364-369
7. Reni, M., Cereda, S., and Galli, L. (2007) PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen. Cancer Lett. 256, 25-28
8. Vincenzi, B., Schiavon, G., Pantano, F., Santini, D., and Tonini, G. (2008) Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat. Clin. Pract. Oncol. 5, 455-465
9. Redon, C. E., Nakamura, A. J., Zhang, Y. W., Ji, J. J., Bonner, W. M., Kinders, R. J., Parchment, R. E., Doroshow, J. H., and Pommier, Y. (2010) Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin. Cancer Res. 16, 4532-4542
10. Ding, H. F., and Fisher, D. E. (1998) Mechanisms of p53-mediated apoptosis. Crit. Rev. Oncog 9, 83-98
11. Oren, M. (2003) Decision making by p53. Life, death and cancer. Cell Death Differ. 10, 431-442
12. Zawacka-Pankau, J., Krachulec, J., Grulkowski, I., Bielawski, K. P., and Selivanova, G. (2008) The p53-mediated cytotoxicity of photodynamic therapy of cancer. Recent advances. Toxicol. Appl. Pharmacol. 232, 487-497
13. Lu, C., and El-Deiry, W. S. (2009) Targeting p53 for enhanced radio-and chemo-sensitivity. Apoptosis 14, 597-606
14. Atsumi, Y., Fujimori, H., Fukuda, H., Inase, A., Shinohe, K., Yoshioka, Y., Shikanai, M., Ichijima, Y., Unno, J., Mizutani, S., Tsuchiya, N., Hippo, Y., Nakagama, H., Masutani, M., Teraoka, H., and Yoshioka, K. (2011) Onset of quiescence following p53 mediated down-regulation of H2AX in normal cells. PLoS ONE 6, e23432
15. Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., and Sherr, C. J. (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659
16. Todaro, G. J., and Green, H. (1963) Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J. Cell Biol. 17, 299-313
17. Lukas, C., Melander, F., Stucki, M., Falck, J., Bekker-Jensen, S., Goldberg, M., Lerenthal, Y., Jackson, S. P., Bartek, J., and Lukas, J. (2004) Mdc1 couples DNA double-strand break recognition by Nbs1 with its H2AXdependent chromatin retention. EMBO J. 23, 2674-2683
18. Dimitrova, N., and de Lange, T. (2006) MDC1 accelerates nonhomologous end-joining of dysfunctional telomeres. Genes Dev. 20, 3238-3243
19. Ichijima, Y., Yoshioka, K., Yoshioka, Y., Shinohe, K., Fujimori, H., Unno, J., Takagi, M., Goto, H., Inagaki, M., Mizutani, S., and Teraoka, H. (2010) DNA lesions induced by replication stress trigger mitotic aberration and tetraploidy development. PLoS ONE 5, e8821
20. Yoshioka, K., Yoshioka, Y., and Hsieh, P. (2006) ATR kinase activation mediated by MutSα and MutLα in response to cytotoxic O6-methylguanine adducts. Mol. Cell 22, 501-510
21. Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J. M., Viña, J., Blasco, M. A., and Serrano, M. (2007) Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448, 375-379
22. Matheu, A., Maraver, A., and Serrano, M. (2008) The Arf/p53 pathway in cancer and aging. Cancer Res. 68, 6031-6034
23. Pommier, Y., Leo, E., Zhang, H., and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421-433
24. Pommier, Y. (2006) Topoisomerase I inhibitors. Camptothecins and beyond. Nat. Rev. Cancer 6, 789-802
25. Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K. J., Fachinetti, D., Bermejo, R., Cocito, A., Costanzo, V., and Lopes, M. (2012) Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat. Struct. Mol. Biol. 19, 417-423
26. Rao, V. A., Fan, A. M., Meng, L., Doe, C. F., North, P. S., Hickson, I. D., and Pommier, Y. (2005) Phosphorylation of BLM, dissociation from topoisomerase IIIα, and colocalization with γ-H2AX after topoisomerase I-induced replication damage. Mol. Cell. Biol. 25, 8925-8937
27. Sugimura, K., Takebayashi, S., Taguchi, H., Takeda, S., and Okumura, K. (2008) PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J. Cell Biol. 183, 1203-1212
28. Hochegger, H., Dejsuphong, D., Fukushima, T., Morrison, C., Sonoda, E., Schreiber, V., Zhao, G. Y., Saberi, A., Masutani, M., Adachi, N., Koyama, H., de Murcia, G., and Takeda, S. (2006) Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells. EMBO J. 25, 1305-1314
29. Zhang, Y. W., Regairaz, M., Seiler, J. A., Agama, K. K., Doroshow, J. H., and Pommier, Y. (2011) Poly(ADP-ribose) polymerase and XPFERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res. 39, 3607-3620
30. Yoshioka, K., Atsumi, Y., Fukuda, H., Masutani, M., and Teraoka, H. (2012) The quiescent cellular state is Arf/p53-dependent and associated with H2AX downregulation and genome stability. Int. J. Mol. Sci. 13, 6492-6506
31. Fujimori, H., Shikanai, M., Teraoka, H., Masutani, M., and Yoshioka, K. (2012) Induction of cancerous stem cells during embryonic stem cell differentiation. J. Biol. Chem. 287, 36777-36791
32. Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., and Gu, W. (2012) Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149, 1269-1283
33. Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Kenzelmann Broz, D., Basak, S., Park, E. J., McLaughlin, M. E., Karnezis, A. N., and Attardi, L. D. (2011) Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571-583
34. Liebermann, D. A., Hoffman, B., and Vesely, D. (2007) p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle 6, 166-170
35. Lowe, S. W., Cepero, E., and Evan, G. (2004) Intrinsic tumour suppression. Nature 432, 307-315
36. Vousden, K. H. (2000) p53. Death star. Cell 103, 691-694
37. Zhou, B. B., and Elledge, S. J. (2000) The DNA damage response. Putting checkpoints in perspective. Nature 408, 433-439
38. Shiloh, Y. (2003) ATM and related protein kinases. Safeguarding genome integrity. Nat. Rev. Cancer 3, 155-168
39. Kastan, M. B., and Lim, D. S. (2000) The many substrates and functions of ATM. Nat. Rev. Mol. Cell Biol. 1, 179-186
40. Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., and Pommier, Y. (2008) γH2AX and cancer. Nat. Rev. Cancer 8, 957-967
41. Bassing, C. H., and Alt, F. W. (2004) H2AX may function as an anchor to hold broken chromosomal DNA ends in close proximity. Cell Cycle 3, 149-153
42. Kinner, A., Wu, W., Staudt, C., and Iliakis, G. (2008) γ-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 36, 5678-5694